This study tests VE202, a medicine, in patients with mild-to-moderate ulcerative colitis (UC). UC is a disease that causes inflammation in the colon. The study will check if VE202 is safe, helps with UC symptoms, and affects gut bacteria. It is a Phase 2 double-blind trial, meaning neither doctors nor patients know who gets the real medicine or a placebo (a sugar pill). Participants will take VE202 or placebo for either 8 or 2 weeks, and safety will be monitored for 1 year.

• The study lasts up to 1 year, with treatment for either 2 or 8 weeks.
• You must be between 18-75 years old with a confirmed UC diagnosis.
• No previous biologic treatments or recent use of probiotics are allowed.

Participants with allergies to VE202 or other conditions like Crohn's disease or certain infections cannot join. If you're eligible and choose to participate, the study will monitor your condition closely, but remember that all studies carry some risks. Check with your doctor if this study is a good fit for you.